Depression - Articles - Page 9

RESEARCH UPDATE

Side Effects in Depression

October 30, 2022

Fernando Espí Forcén, MD. Dr. Forcén has no financial relationships with companies related to this material.

Side effects are burdensome to patients, but do they also get in the way of recovery? This study sought to clarify how side effects change over time and whether they impede recovery in major depressive disorder.

EXPERT Q&A

The Enduring Value of Talking Therapy

October 30, 2022

Allen Frances, MD

Allen Frances, MD. Dr. Frances has no financial relationships with companies related to this material.

An interview with Dr. Allen Frances about the enduring value of talk therapy, and insights into how therapy is being used in modern clinical practice.

Throwback Thursday: Ginger Ale and Normal Hallucinations

October 13, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Is it ever normal to hear voices and is ginger ale really the best treatment for nausea?

How to Identify and Treat Apathy and Late-Life Depression

October 1, 2022

Rehan Aziz, MD and Julia Cromwell, MD

Rehan Aziz, MD. associate program director, geriatric psychiatry fellowship program, Jersey Shore University Medical Center; associate professor of psychiatry and neurology, Hackensack Meridian School of Medicine, Nutley, NJ. Julia Cromwell, MD. Inpatient geriatric psychiatrist, Mass General Brigham Salem Hospital, Salem, MA. Dr. Aziz and Dr. Cromwell, authors of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

We provide tips on distinguishing between apathy and depression, as well as recommendations on how to manage these disorders.

Aripiprazole in Depression: The Right Dose

September 25, 2022

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dosing recommendations for aripiprazole vary widely in depression, from 2 mg to 15 mg, but this meta-analysis finds a sweet spot in the lower range.

CARLAT WEBINAR

Treatment of Depression During Pregnancy

September 13, 2022

Victoria Hendrick, MD

0.50 CME Credits. How to have a discussion with patients and to document risks and benefits to educate them the baseline risk of depression treatment in pregnancy.

SAINT TMS Cleared for Treatment-Resistant Depression

September 12, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

How to Interview the Older Patient

August 29, 2022

Stephanie Collier, MD and Rehan Aziz, MD.

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This podcast will cover additional factors to consider when evaluating older patients.

Psychosis During Depression

August 23, 2022

Conrad M. Swartz, MD, PhD

Conrad M. Swartz, MD, PhD. Professor Emeritus, Southern Illinois University, Springfield, IL. Dr. Swartz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychotic depression is difficult to detect, and antipsychotics are not as effective in this condition as we’d like to think. Conrad Swartz explains why 1 in 3 cases of psychotic depression are missed, its complex relationship to trauma, and how to treat it.

Benzodiazepines: A Reevaluation of Their Benefits and Dangers

August 23, 2022

Carl Salzman MD

Carl Salzman, MD

Professor of Psychiatry at Harvard Medical School and past chairman of the American Psychiatric Association Benzodiazepine Task Force. Interview by Marcia L. Zuckerman, MD. Board member of The Carlat Psychiatry Report; outpatient psychiatrist, Hallmark Health, Medford, MA; clinical assistant professor in psychiatry, Tufts School of Medicine. Edited by Chris Aiken, MD. Editor-in-Chief of TCPR; practicing psychiatrist, Winston-Salem, NC.

Drs. Salzman, Zuckerman, and Aiken have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Former Chairman of the American Psychiatric Association Benzodiazepine Task Force Carl Salzman explains the legitimate medical use of benzodiazepines and their relevance in psychiatric practice.